Press Releases GSK plc Deutsche Boerse AG

Equities

GS71

GB00BN7SWP63

Market Closed - Deutsche Boerse AG Other stock markets 03:41:18 2024-04-26 pm EDT			5-day change	1st Jan Change
19.15 ^EUR	+0.52%		+3.79%	+14.78%

Apr. 25	Sector Update: Health Care Stocks Drop in Afternoon Trading	MT
Apr. 25	GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

US FDA accepts for priority review GSK's application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer \| GSK	Apr. 24	AQ
GSK : Director/Pdmr Shareholding - Form 6-K	Apr. 19	PU
EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments \| GSK	Apr. 17	AQ
New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade \| GSK	Apr. 17	AQ
GSK : EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments - Form 6-K	Apr. 17	PU
GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA \| GSK	Apr. 17	AQ
GSK : EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments	Apr. 17	PU
GSK : New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade	Apr. 17	PU
GSK : 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA - Form 6-K	Apr. 16	PU
GSK : 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA	Apr. 16	PU
GSK : Q1 2024 pre announcement aide memoire	Apr. 11	PU
WuXi Biologics Reports Solid 2023 Annual Results	Mar. 27	AQ
GSK : Director/Pdmr Shareholding - Form 6-K	Mar. 22	PU
Haleon to buy shares from Pfizer as US pharma giant reduces its stake	Mar. 19	AQ
GSK plc - Positive RUBY phase III data show potential for Jemperli combinations in more patients with primary advanced or recurrent endometrial cancer	Mar. 18	AQ
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer	Mar. 16	BU
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise	Mar. 07	BU
GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma \| GSK	Mar. 07	AQ
GSK : ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges	Mar. 06	PU
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses \| GSK	Mar. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : 2023 ended on a strong note; medium- to long-term guidance raised

February 02, 2024 at 09:40 am EST